Based around 34 major chemotypes, the Peakexplorer library has been designed to address gaps in commercially available compound collections and to provide greater diversity in drug discovery
Peakdale Molecular announces the completion of its Peakexplorer G-protein coupled receptor (GPCR) library of screening compounds.
G6, its sixth and final release, now brings the total collection to 6500 fully characterised and purified, drug-like compounds.
Based around 34 major chemotypes, the Peakexplorer library has been designed specifically to address gaps in commercially available compound collections and to provide greater diversity in drug discovery.
The Peakexplorer GPCR library's success underlines Peakdale's customer focus and expertise in less commonly used chemistries and incorporates proprietary scaffolds - some of which were designed non-exclusively with customers.
These synthetic capabilities have been strengthened through the collaboration with De Novo Pharmaceuticals, bringing in silico pharmacophore modelling and virtual screening algorithms to enhance the library design and characterisation processes.
Commenting on the library's success, Kim Morrison, CEO, noted, "This collaboration has been extremely successful and has provided us with a great learning curve on running these type of partnerships.
"We are using this experience to further refine our approach to designing focused arrays against specific targets to speed up drug discovery".
Having completed the Peakexplorer GPCR range, Peakdale is now turning its attention to synthesising a kinase library and also designing Peakfinder chemogenetic arrays.
These will be collections of drug-like molecules, selectively designed to enhance receptor-ligand interactions.
The combination of Peakdale's synthetic and medicinal chemistry expertise, with the addition of in-house computational design tools, will mean these arrays will be based around novel molecules and incorporate Admet filters.
This will ultimately result in robust molecules that will allow for faster, more cost-effective lead optimisation in customers' discovery programmes.
Peakdale Molecular was founded in 1992.
Today, the company's customers include 18 of the top 20 global pharmaceutical companies and an increasing number of biotechnology companies.
Its teams of chemists combine experience in pharmaceutical R and D and process development, medicinal chemistry, parallel synthesis and fine chemicals to deliver unique chemistry solutions to a range of drug discovery challenges.
Application of less commonly used chemistry, including high temperature/pressure reactions, proprietary heterocyclic chemistry and nucleoside synthesis, enables Peakdale's chemists to generate unique compounds for drug discovery.
Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis and contract research.
